Labetalol
- Generic Name
- Labetalol
- Brand Names
- Trandate
- Drug Type
- Small Molecule
- Chemical Formula
- C19H24N2O3
- CAS Number
- 36894-69-6
- Unique Ingredient Identifier
- R5H8897N95
- Background
Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.
Labetalol was granted FDA approval on 1 August 1984.
- Indication
Labetalol injections are indicated to control blood pressure in severe hypertension. Labetalol tablets are indicated alone or in combination with antihypertensives like thiazides and loop diuretics to manage hypertension.
- Associated Conditions
- Chronic Stable Angina Pectoris, Hypertension, Hypertensive Emergency, Hypertensive crisis, Pheochromocytoma, Subarachnoid Hemorrhage
- Associated Therapies
- -
Treatment Targets for Chronic Hypertension in Pregnancy
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Weill Medical College of Cornell University
- Registration Number
- NCT00194974
- Locations
- 🇺🇸
The New York PresbyterianHospital-Weill Medical College of Cornell University, New York, New York, United States
Effects of Labetalol on Human Cocaine Use - 8
- Conditions
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Registration Number
- NCT00000291
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
Effects of Labetalol on Nicotine Administration in Humans - 14
- Conditions
- First Posted Date
- 1999-09-21
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Registration Number
- NCT00000297
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.